Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Sold by Royce & Associates LP

Royce & Associates LP decreased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 12.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 78,703 shares of the company’s stock after selling 11,413 shares during the quarter. Royce & Associates LP owned 0.14% of Harmony Biosciences worth $3,148,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new position in shares of Harmony Biosciences during the 3rd quarter worth approximately $235,000. CWA Asset Management Group LLC acquired a new position in Harmony Biosciences during the third quarter worth $576,000. Hedeker Wealth LLC lifted its holdings in Harmony Biosciences by 3.7% during the third quarter. Hedeker Wealth LLC now owns 75,287 shares of the company’s stock valued at $3,011,000 after purchasing an additional 2,662 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Harmony Biosciences by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,931 shares of the company’s stock valued at $437,000 after purchasing an additional 4,259 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in shares of Harmony Biosciences by 8,867.7% during the third quarter. Nisa Investment Advisors LLC now owns 5,560 shares of the company’s stock worth $222,000 after purchasing an additional 5,498 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 price objective on shares of Harmony Biosciences in a report on Tuesday, October 29th. Mizuho lifted their price target on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, October 10th. UBS Group assumed coverage on Harmony Biosciences in a research note on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price objective for the company. Cantor Fitzgerald lifted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Finally, Raymond James reiterated an “outperform” rating and issued a $40.00 target price on shares of Harmony Biosciences in a research report on Thursday, October 10th. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $47.00.

Insider Activity

In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of the company’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total value of $869,943.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 30.80% of the company’s stock.

Harmony Biosciences Price Performance

Shares of HRMY stock opened at $33.07 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company has a market capitalization of $1.89 billion, a PE ratio of 15.67, a price-to-earnings-growth ratio of 0.62 and a beta of 0.77. The firm’s 50-day moving average is $35.98 and its two-hundred day moving average is $33.51. Harmony Biosciences Holdings, Inc. has a 12 month low of $27.10 and a 12 month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. The firm had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s revenue for the quarter was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 EPS. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.36 earnings per share for the current year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.